@phdthesis{ZimmermannneePapp2024,
  author    = {Zimmermann [n{\´e}e Papp], Lena},
  title     = {Platelets as modulators of blood-brain barrier disruption and inflammation in the pathophysiology of ischemic stroke},
  doi       = {10.25972/OPUS-30285},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-302850},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Ischemia-reperfusion injury (I/R injury) is a common complication in ischemic stroke (IS) treatment, which is characterized by a paradoxical perpetuation of tissue damage despite the successful re-establishment of vascular perfusion. This phenomenon is known to be facilitated by the detrimental interplay of platelets and inflammatory cells at the vascular interface. However, the spatio-temporal and molecular mechanisms underlying these cellular interactions and their contribution to infarct progression are still incompletely understood. Therefore, this study intended to clarify the temporal mechanisms of infarct growth after cerebral vessel recanalization. The data presented here could show that infarct progression is driven by early blood-brain-barrier perturbation and is independent of secondary thrombus formation. Since previous studies unravelled the secretion of platelet granules as a molecular mechanism of how platelets contribute to I/R injury, special emphasis was placed on the role of platelet granule secretion in the process of barrier dysfunction. By combining an in vitro approach with a murine IS model, it could be shown that platelet α-granules exerted endothelial-damaging properties, whereas their absence (NBEAL2-deficiency) translated into improved microvascular integrity. Hence, targeting platelet α-granules might serve as a novel treatment option to reduce vascular integrity loss and diminish infarct growth despite recanalization. Recent evidence revealed that pathomechanisms underlying I/R injury are already instrumental during large vessel occlusion. This indicates that penumbral tissue loss under occlusion and I/R injury during reperfusion share an intertwined relationship. In accordance with this notion, human observational data disclosed the presence of a neutrophil dominated immune response and local platelet activation and secretion, by the detection of the main components of platelet α-granules, within the secluded vasculature of IS patients. These initial observations of immune cells and platelets could be further expanded within this thesis by flow cytometric analysis of local ischemic blood samples. Phenotyping of immune cells disclosed a yet unknown shift in the lymphocyte population towards CD4+ T cells and additionally corroborated the concept of an immediate intravascular immune response that is dominated by granulocytes. Furthermore, this thesis provides first-time evidence for the increased appearance of platelet-leukocyte-aggregates within the secluded human vasculature. Thus, interfering with immune cells and/or platelets already under occlusion might serve as a potential strategy to diminish infarct expansion and ameliorate clinical outcome after IS.},
  subject      = {Schlaganfall},
  language  = {en}
}
@phdthesis{Goeser2024,
  author    = {G{\"o}ser, Marlies},
  title     = {"Eignet sich die kritische Flimmerfrequenz zur Diagnose einer minimal hepatischen Enzephalopathie?"},
  doi       = {10.25972/OPUS-34936},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-349363},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Korrelation und Kontingenzpr{\"u}fung von Kritischer Flimmerfrequenz als diagnostischem Mittel bei minimal hepatischer Enzephalopathie mit anderen etablierten diagnostischen Mitteln und beschreibenden Parametern. In den Ergebnissen lediglich Korrelation mit Alertness Testung in der Testbatterie. Minimal hepatische Enzephalopathie braucht zur Diagnostik mindestens 2 verschiedene erg{\"a}nzende diagnostische Verfahren (neuropsychologisch und -physiologisch), um sicher entdeckt werden zu k{\"o}nnen. Bei nur einem Testverfahren blieben zahlreiche Betroffene unentdeckt. M{\"o}glicherweise ist das verschiedenen pathophysiologischen Subgruppen geschuldet.},
  subject      = {Encephalopathia hepatica},
  language  = {de}
}
@article{WiesslerTalucciPiroetal.2024,
  author    = {Wiessler, Anna-Lena and Talucci, Ivan and Piro, Inken and Seefried, Sabine and H{\"o}rlin, Verena and Baykan, Bet{\"u}l B. and T{\"u}z{\"u}n, Erdem and Schaefer, Natascha and Maric, Hans M. and Sommer, Claudia and Villmann, Carmen},
  title     = {Glycine receptor β-targeting autoantibodies contribute to the pathology of autoimmune diseases},
  series = {Neurology: Neuroimmunology \& Neuroinflammation},
  volume    = {11},
  journal   = {Neurology: Neuroimmunology \& Neuroinflammation},
  number    = {2},
  doi       = {10.1212/NXI.0000000000200187},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-349958},
  year      = {2024},
  abstract  = {Background and Objectives Stiff-person syndrome (SPS) and progressive encephalomyelitis with rigidity and myoclonus (PERM) are rare neurologic disorders of the CNS. Until now, exclusive GlyRα subunit-binding autoantibodies with subsequent changes in function and surface numbers were reported. GlyR autoantibodies have also been described in patients with focal epilepsy. Autoimmune reactivity against the GlyRβ subunits has not yet been shown. Autoantibodies against GlyRα1 target the large extracellular N-terminal domain. This domain shares a high degree of sequence homology with GlyRβ making it not unlikely that GlyRβ-specific autoantibody (aAb) exist and contribute to the disease pathology. Methods In this study, we investigated serum samples from 58 patients for aAb specifically detecting GlyRβ. Studies in microarray format, cell-based assays, and primary spinal cord neurons and spinal cord tissue immunohistochemistry were performed to determine specific GlyRβ binding and define aAb binding to distinct protein regions. Preadsorption approaches of aAbs using living cells and the purified extracellular receptor domain were further used. Finally, functional consequences for inhibitory neurotransmission upon GlyRβ aAb binding were resolved by whole-cell patch-clamp recordings. Results Among 58 samples investigated, cell-based assays, tissue analysis, and preadsorption approaches revealed 2 patients with high specificity for GlyRβ aAb. Quantitative protein cluster analysis demonstrated aAb binding to synaptic GlyRβ colocalized with the scaffold protein gephyrin independent of the presence of GlyRα1. At the functional level, binding of GlyRβ aAb from both patients to its target impair glycine efficacy. Discussion Our study establishes GlyRβ as novel target of aAb in patients with SPS/PERM. In contrast to exclusively GlyRα1-positive sera, which alter glycine potency, aAbs against GlyRβ impair receptor efficacy for the neurotransmitter glycine. Imaging and functional analyses showed that GlyRβ aAbs antagonize inhibitory neurotransmission by affecting receptor function rather than localization.},
  language  = {en}
}
@article{BreyerGruenerKleinetal.2024,
  author    = {Breyer, Maximilian and Gr{\"u}ner, Julia and Klein, Alexandra and Finke, Laura and Klug, Katharina and Sauer, Markus and {\"U}{\c{c}}eyler, Nurcan},
  title     = {\(In\) \(vitro\) characterization of cells derived from a patient with the GLA variant c.376A>G (p.S126G) highlights a non-pathogenic role in Fabry disease},
  series = {Molecular Genetics and Metabolism Reports},
  volume    = {38},
  journal   = {Molecular Genetics and Metabolism Reports},
  issn      = {22144269},
  doi       = {10.1016/j.ymgmr.2023.101029},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-350295},
  year      = {2024},
  abstract  = {Highlights • The GLA variant S126G is not associated with Fabry symptoms in the presented case • S126G has no effect on α-GAL A activity or Gb3 levels in this patient • S126G sensory neurons show no electrophysiological abnormalities Abstract Fabry disease (FD) is a life-limiting disorder characterized by intracellular globotriaosylceramide (Gb3) accumulations. The underlying α-galactosidase A (α-GAL A) deficiency is caused by variants in the gene GLA. Variants of unknown significance (VUS) are frequently found in GLA and challenge clinical management. Here, we investigated a 49-year old man with cryptogenic lacunar cerebral stroke and the chance finding of the VUS S126G, who was sent to our center for diagnosis and initiation of a costly and life-long FD-specific treatment. We combined clinical examination with in vitro investigations of dermal fibroblasts (HDF), induced pluripotent stem cells (iPSC), and iPSC-derived sensory neurons. We analyzed α-GAL A activity in iPSC, Gb3 accumulation in all three cell types, and action potential firing in sensory neurons. Neurological examination and small nerve fiber assessment was normal except for reduced distal skin innervation. S126G iPSC showed normal α-GAL A activity compared to controls and no Gb3 deposits were found in all three cell types. Baseline electrophysiological characteristics of S126G neurons showed no difference compared to healthy controls as investigated by patch-clamp recordings. We pioneer multi-level cellular characterization of the VUS S126G using three cell types derived from a patient and provide further evidence for the benign nature of S126G in GLA, which is of great importance in the management of such cases in clinical practice.},
  language  = {en}
}
@article{JaenschEvdokimovEgenolfetal.2024,
  author    = {J{\"a}nsch, Sarah and Evdokimov, Dimitar and Egenolf, Nadine and Meyer zu Altenschildesche, Caren and Kreß, Luisa and {\"U}{\c{c}}eyler, Nurcan},
  title     = {Distinguishing fibromyalgia syndrome from small fiber neuropathy: a clinical guide},
  series = {Pain Reports},
  volume    = {9},
  journal   = {Pain Reports},
  number    = {1},
  doi       = {10.1097/PR9.0000000000001136},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-350306},
  year      = {2024},
  abstract  = {Introduction: Fibromyalgia syndrome (FMS) and small fiber neuropathy (SFN) are distinct pain conditions that share commonalities and may be challenging as for differential diagnosis. Objective: To comprehensively investigate clinical characteristics of women with FMS and SFN to determine clinically applicable parameters for differentiation. Methods: We retrospectively analyzed medical records of 158 women with FMS and 53 with SFN focusing on pain-specific medical and family history, accompanying symptoms, additional diseases, and treatment. We investigated data obtained using standardized pain, depression, and anxiety questionnaires. We further analyzed test results and findings obtained in standardized small fiber tests. Results: FMS patients were on average ten years younger at symptom onset, described higher pain intensities requiring frequent change of pharmaceutics, and reported generalized pain compared to SFN. Pain in FMS was accompanied by irritable bowel or sleep disturbances, and in SFN by paresthesias, numbness, and impaired glucose metabolism (P < 0.01 each). Family history was informative for chronic pain and affective disorders in FMS (P < 0.001) and for neurological disorders in SFN patients (P < 0.001). Small fiber pathology in terms of skin denervation and/or thermal sensory threshold elevation was present in 110/158 (69.7 \%) FMS patients and 39/53 (73.6 \%) SFN patients. FMS patients mainly showed proximally reduced skin innervation and higher corneal nerve branch densities (p<0.001) whereas SFN patients were characterized by reduced cold detection and prolonged electrical A-delta conduction latencies (P < 0.05). Conclusions: Our data show that FMS and SFN differ substantially. Detailed pain, drug and family history, investigating blood glucose metabolism, and applying differential small fiber tests may help to improve diagnostic differentiation and targeted therapy.},
  language  = {en}
}
@article{HartmannsbergerScribaGuidolinetal.2024,
  author    = {Hartmannsberger, Beate and Scriba, Sabrina and Guidolin, Carolina and Becker, Juliane and Mehling, Katharina and Doppler, Kathrin and Sommer, Claudia and Rittner, Heike L.},
  title     = {Transient immune activation without loss of intraepidermal innervation and associated Schwann cells in patients with complex regional pain syndrome},
  series = {Journal of Neuroinflammation},
  volume    = {21},
  journal   = {Journal of Neuroinflammation},
  doi       = {10.1186/s12974-023-02969-6},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-357164},
  year      = {2024},
  abstract  = {Background Complex regional pain syndrome (CRPS) develops after injury and is characterized by disproportionate pain, oedema, and functional loss. CRPS has clinical signs of neuropathy as well as neurogenic inflammation. Here, we asked whether skin biopsies could be used to differentiate the contribution of these two systems to ultimately guide therapy. To this end, the cutaneous sensory system including nerve fibres and the recently described nociceptive Schwann cells as well as the cutaneous immune system were analysed. Methods We systematically deep-phenotyped CRPS patients and immunolabelled glabrous skin biopsies from the affected ipsilateral and non-affected contralateral finger of 19 acute (< 12 months) and 6 chronic (> 12 months after trauma) CRPS patients as well as 25 sex- and age-matched healthy controls (HC). Murine foot pads harvested one week after sham or chronic constriction injury were immunolabelled to assess intraepidermal Schwann cells. Results Intraepidermal Schwann cells were detected in human skin of the finger—but their density was much lower compared to mice. Acute and chronic CRPS patients suffered from moderate to severe CRPS symptoms and corresponding pain. Most patients had CRPS type I in the warm category. Their cutaneous neuroglial complex was completely unaffected despite sensory plus signs, e.g. allodynia and hyperalgesia. Cutaneous innate sentinel immune cells, e.g. mast cells and Langerhans cells, infiltrated or proliferated ipsilaterally independently of each other—but only in acute CRPS. No additional adaptive immune cells, e.g. T cells and plasma cells, infiltrated the skin. Conclusions Diagnostic skin punch biopsies could be used to diagnose individual pathophysiology in a very heterogenous disease like acute CRPS to guide tailored treatment in the future. Since numbers of inflammatory cells and pain did not necessarily correlate, more in-depth analysis of individual patients is necessary.},
  language  = {en}
}
@phdthesis{Hoerner2024,
  author    = {H{\"o}rner, Michaela},
  title     = {The role of inflammation in hereditary spastic paraplegia type 11},
  doi       = {10.25972/OPUS-30336},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-303368},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Hereditary spastic paraplegias (HSPs) are genetically-determined, neurodegenerative disorders characterized by progressive weakness and spasticity of the lower limbs. Spastic paraplegia type 11 (SPG11) is a complicated form of HSP, which is caused by mutations in the SPG11 gene encoding spatacsin, a protein possibly involved in lysosomal reformation. Based on our previous studies demonstrating that secondary neuroinflammation can be a robust amplifier of various genetically-mediated diseases of both the central and peripheral nervous system, we here test the possibility that neuroinflammation may modify the disease outcome also in a mouse model for SPG11. Spg11-knockout (Spg11-/-) mice develop early walking pattern and behavioral abnormalities, at least partially reflecting motor, and behavioral changes typical for patients. Furthermore, we detected a progressive increase in axonal damage and axonal spheroid formation in the white and grey matter compartments of the central nervous system of Spg11-/- mice. This was accompanied by a concomitant substantial increase of secondary inflammation by cytotoxic CD8+ and CD4+ T-lymphocytes. We here provide evidence that disease-related changes can be ameliorated/delayed by the genetic deletion of the adaptive immune system. Accordingly, we provide evidence that repurposing clinically approved immunomodulators (fingolimod/FTY720 or teriflunomide), that are in use for treatment of multiple sclerosis (MS), also improve disease symptoms in mice, when administered in an early (before neural damage) or late (after/during neural damage) treatment regime. This work provides strong evidence that immunomodulation can be a therapeutic option for the still untreatable SPG11, including its typical neuropsychological features. This poses the question if inflammation is not only a disease amplifier in SPG11 but can act as a unifying factor also for other genetically mediated disorders of the CNS. If true, this may pave the way to therapeutic options in a wide range of still untreatable, primarily genetic, neurological disorders by repurposing approved immunomodulators.},
  subject      = {Entz{\"u}ndung},
  language  = {en}
}
@article{SteinhardtCejkaChenetal.2024,
  author    = {Steinhardt, Maximilian J. and Cejka, Vladimir and Chen, Mengmeng and B{\"a}uerlein, Sabrina and Sch{\"a}fer, Julia and Adrah, Ali and Ihne-Schubert, Sandra M. and Papagianni, Aikaterini and Kort{\"u}m, K. Martin and Morbach, Caroline and St{\"o}rk, Stefan},
  title     = {Safety and tolerability of SGLT2 inhibitors in cardiac amyloidosis — a clinical feasibility study},
  series = {Journal of Clinical Medicine},
  volume    = {13},
  journal   = {Journal of Clinical Medicine},
  number    = {1},
  issn      = {2077-0383},
  doi       = {10.3390/jcm13010283},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-356024},
  year      = {2024},
  abstract  = {Sodium-glucose transport protein 2 inhibitors (SGLT2i) slow the progression of renal dysfunction and improve the prognosis of patients with heart failure. Amyloidosis constitutes an important subgroup for which evidence is lacking. Amyloidotic fibrils originating from misfolded transthyretin and light chains are the causal agents in ATTR and AL amyloidosis. In these most frequent subtypes, cardiac involvement is the most common organ manifestation. Because cardiac and renal function frequently deteriorate over time, even under best available treatment, SGLT2i emerge as a promising treatment option due to their reno- and cardioprotective properties. We retrospectively analyzed patients with cardiac amyloidosis, who received either dapagliflozin or empagliflozin. Out of 79 patients, 5.1\% had urinary tract infections; 2 stopped SGLT2i therapy; and 2.5\% died unrelated to the intake of SGLT2i. No genital mycotic infections were observed. As expected, a slight drop in the glomerular filtration rate was noted, while the NYHA functional status, cardiac and hepatic function, as well as the 6 min walk distance remained stable over time. These data provide a rationale for the use of SGLT2i in patients with amyloidosis and concomitant cardiac or renal dysfunction. Prospective randomized data are desired to confirm safety and to prove efficacy in this increasingly important group of patients.},
  language  = {en}
}
@phdthesis{Behne2024,
  author    = {Behne, Robert Stefan Friedrich},
  title     = {Development Of A Human iPSC-Derived Cortical Neuron Model Of Adaptor- Protein-Complex-4-Deficiency},
  doi       = {10.25972/OPUS-35139},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-351390},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Adaptor-protein-4-deficiency (AP-4-deficiency) is an autosomal-recessive childhood- onset form of complicated hereditary spastic paraplegia (HSP) caused by bi-allelic loss- of-function mutations in one of the four subunits of the AP-4-complex. These four conditions are named SPG47 (AP4B1, OMIM \#614066), SPG50 (AP4M1, OMIM \#612936), SPG51 (AP4E1, OMIM \#613744) and SPG52 (AP4S1, OMIM \#614067), respectively and all present with global developmental delay, progressive spasticity and seizures. Imaging features include a thinning of the corpus callosum, ventriculomegaly and white matter changes. AP-4 is a highly conserved heterotetrameric complex, which is responsible for polarized sorting of transmembrane cargo including the autophagy- related protein 9 A (ATG9A). Loss of any of the four subunits leads to an instable complex and defective sorting of AP-4-cargo. ATG9A is implicated in autophagosome formation and neurite outgrowth. It is missorted in AP-4-deficient cells and CNS-specific knockout of Atg9a in mice results in a phenotype reminiscent of AP-4-deficiency. However, the AP-4-related cellular phenotypes including ATG9A missorting have not been investigated in human neurons. Thus, the aim of this study is to provide the first human induced pluripotent stem cell- derived (iPSC) cortical neuron model of AP-4-deficiency to explore AP-4-related phenotypes in preparation for a high-content screening. Under the hypothesis that AP-4- deficiency leads to ATG9A missorting, elevated ATG9A levels, impaired autophagy and neurite outgrowth in human iPSC-derived cortical neurons, in vitro biochemical and imaging assays including automated high-content imaging and analysis were applied. First, these phenotypes were investigated in fibroblasts from three patients with compound heterozygous mutations in the AP4B1 gene and their sex-matched parental controls. The same cell lines were used to generate iPSCs and differentiate them into human excitatory cortical neurons. This work shows that ATG9A is accumulating in the trans-Golgi-network in AP-4- deficient human fibroblasts and that ATG9A levels are increased compared to parental controls and wild type cells suggesting a compensatory mechanism. Protein levels of the AP4E1-subunit were used as a surrogate marker for the AP-4-complex and were decreased in AP-4-deficient fibroblasts with co-immunoprecipitation confirming the instability of the complex. Lentiviral re-expression of the AP4B1-subunit rescues this corroborating the fact that a stable AP-4-complex is needed for ATG9A trafficking. Surprisingly, autophagic flux was present in AP-4-deficient fibroblasts under nutrient- rich and starvation conditions. These phenotypic markers were evaluated in iPSC-derived cortical neurons and here, a robust accumulation of ATG9A in the juxtanuclear area was seen together with elevated ATG9A protein levels. Strikingly, assessment of autophagy markers under nutrient-rich conditions showed alterations in AP-4-deficient iPSC- derived cortical neurons indicating dysfunctional autophagosome formation. These findings point towards a neuron-specific impairment of autophagy and need further investigation. Adding to the range of AP-4-related phenotypes, neurite outgrowth and branching are impaired in AP-4-deficient iPSC-derived cortical neurons as early as 24h after plating and together with recent studies point towards a distinct role of ATG9A in neurodevelopment independent of autophagy. Together, this work provides the first patient-derived neuron model of AP-4-deficiency and shows that ATG9A is sorted in an AP-4-dependent manner. It establishes ATG9A- related phenotypes and impaired neurite outgrowth as robust markers for a high-content screening. This disease model holds the promise of providing a platform to further study AP-4-deficiency and to search for novel therapeutic targets.},
  subject      = {Adaptorproteine},
  language  = {en}
}
@phdthesis{Knorr2024,
  author    = {Knorr, Susanne},
  title     = {Pathophysiology of early-onset isolated dystonia in a DYT-TOR1A rat model with trauma-induced dystonia-like movements},
  doi       = {10.25972/OPUS-20609},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-206096},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {Early-onset torsion dystonia (DYT-TOR1A, DYT1) is an inherited hyperkinetic movement disorder caused by a mutation of the TOR1A gene encoding the torsinA protein. DYT-TOR1A is characterized as a network disorder of the central nervous system (CNS), including predominantly the cortico-basal ganglia-thalamo-cortical loop resulting in a severe generalized dystonic phenotype. The pathophysiology of DYTTOR1A is not fully understood. Molecular levels up to large-scale network levels of the CNS are suggested to be affected in the pathophysiology of DYT-TOR1A. The reduced penetrance of 30\% - 40\% indicates a gene-environmental interaction, hypothesized as "second hit". The lack of appropriate and phenotypic DYT-TOR1A animal models encouraged us to verify the "second hit" hypothesis through a unilateral peripheral nerve trauma of the sciatic nerve in a transgenic asymptomatic DYT-TOR1A rat model (∆ETorA), overexpressing the human mutated torsinA protein. In a multiscale approach, this animal model was characterized phenotypically and pathophysiologically. Nerve-injured ∆ETorA rats revealed dystonia-like movements (DLM) with a partially generalized phenotype. A physiomarker of human dystonia, describing increased theta oscillation in the globus pallidus internus (GPi), was found in the entopeduncular nucleus (EP), the rodent equivalent to the human GPi, of nerve-injured ∆ETorA rats. Altered oscillation patterns were also observed in the primary motor cortex. Highfrequency stimulation (HFS) of the EP reduced DLM and modulated altered oscillatory activity in the EP and primary motor cortex in nerve-injured ∆ETorA rats. Moreover, the dopaminergic system in ∆ETorA rats demonstrated a significant increased striatal dopamine release and dopamine turnover. Whole transcriptome analysis revealed differentially expressed genes of the circadian clock and the energy metabolism, thereby pointing towards novel, putative pathways in the pathophysiology of DYTTOR1A dystonia. In summary, peripheral nerve trauma can trigger DLM in genetically predisposed asymptomatic ΔETorA rats leading to neurobiological alteration in the central motor network on multiple levels and thereby supporting the "second hit" hypothesis. This novel symptomatic DYT-TOR1A rat model, based on a DYT-TOR1A genetic background, may prove as a valuable chance for DYT-TOR1A dystonia, to further investigate the pathomechanism in more detail and to establish new treatment strategies.},
  subject      = {Dystonie},
  language  = {en}
}
@phdthesis{Wilhelmi2024,
  author    = {Wilhelmi, Kai Alexander},
  title     = {Untersuchung von Ver{\"a}nderungen der myelinisierten Nervenfasern durch Entmarkung in Haut- und Nervenbiopsien von Patienten mit Polyneuropathie},
  doi       = {10.25972/OPUS-36004},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-360046},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2024},
  abstract  = {In dieser Arbeit wurde durch das immunhistochemische Anf{\"a}rben von nodalen (Natriumkan{\"a}le, NF), paranodalen (Caspr, NF) und internodalen (MBP) Proteinen der in Fingerhautbiopsien vorhanden Nervenfasern untersucht, ob eine Ver{\"a}nderung der typischen Verteilungsmuster dieser Proteine, eine demyelinisierende Polyneuropathie anzeigen kann. Dazu wurden am Universit{\"a}tsklinikum W{\"u}rzburg prospektiv 93 Polyneuropathie-Patienten und 25 Kontrollpersonen rekrutiert. Bei allen Patienten wurden Hautstanzbiospien am Zeigefinger durchgef{\"u}hrt. Bei 35 Patienten mit schweren oder unklaren Verl{\"a}ufen, wurden konsiliarisch Nervus suralis Biopsien durchgef{\"u}hrt. Aus einem Abschnitt von 27 dieser Biopsien, konnten im Rahmen dieser Arbeit Zupfnervenpr{\"a}parate angefertigt und analog zu den Hautbiopsien ausgewertet werden. Aus der Routinediagnostik der Klinik flossen weiterhin die Ergebnisse der elektrophysiologischen Routinediagnostik und der Histologiebefund der Nervus suralis Biopsien in die Auswertung ein. Zusammenfassend kamen ver{\"a}nderte Natriumkanalbanden in Fingerhautbiopsien signifikant h{\"a}ufiger bei Patienten mit elektrophysiologisch als demyelinisierend befundeten Polyneuropathien, als bei Patienten mit elektrophysiologisch als axonal befundeten Polyneuropathien vor. Vielfach fanden sich ver{\"a}nderte Natriumkanalbanden inmitten para- und internodal unauff{\"a}lliger Schn{\"u}rringe und umgekehrt. Diese Beobachtung st{\"u}tzt die bereits in Vorarbeiten vorgeschlagene und in der aktuellen Leitlinie zur Diagnostik f{\"u}r Polyneuropathien aufgegriffene Entit{\"a}t der Paranodopathien (Uncini, Susuki, \& Yuki, 2013). M{\"o}glich w{\"a}re, dass eine ver{\"a}nderte Verteilung der Natriumkan{\"a}le die schnelle Leitf{\"a}higkeit beeintr{\"a}chtigen und somit trotz intakter Bemarkung, elektrophysiologisch das Bild einer demyelinisierenden Neuropathie vermittelt. Ein direkter Zusammenhang zwischen dem Auftreten von doppelten und verl{\"a}ngerten Natriumkanalbanden und einzelnen Messwerten (z.B. Amplituden und Latenzzeiten) fand sich nicht. Auch in den Zupfnervenpr{\"a}paraten der Nervus suralis Biopsien, konnten o.g. Verteilungsmuster untersucht werden. Deren Vorkommen zeigte sich als unabh{\"a}ngig vom elektrophysiologischen und histologischen Befund, von der {\"A}tiologie der PNP und von den gefundenen Ver{\"a}nderungen in den Hautbiopsien des betreffenden Patienten.},
  subject      = {Polyneuropathie},
  language  = {de}
}
@phdthesis{Yuan2023,
  author    = {Yuan, Xidi},
  title     = {Aging and inflammation in the peripheral nervous system},
  doi       = {10.25972/OPUS-23737},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-237378},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Aging is known to be a risk factor for structural abnormalities and functional decline in the nervous system. Characterizing age-related changes is important to identify putative pathways to overcome deleterious effects and improve life quality for the elderly. In this study, the peripheral nervous system of 24-month-old aged C57BL/6 mice has been investigated and compared to 12-month-old adult mice. Aged mice showed pathological alterations in their peripheral nerves similar to nerve biopsies from elderly human individuals, with nerve fibers showing demyelination and axonal damage. Such changes were lacking in nerves of adult 12-month-old mice and adult, non-aged humans. Moreover, neuromuscular junctions of 24-month-old mice showed increased denervation compared to adult mice. These alterations were accompanied by elevated numbers of macrophages in the peripheral nerves of aged mice. The neuroinflammatory conditions were associated with impaired myelin integrity and with a decline of nerve conduction properties and muscle strength in aged mice. To determine the pathological impact of macrophages in the aging mice, macrophage depletion was performed in mice by oral administration of CSF-1R specific kinase (c-FMS) inhibitor PLX5622 (300 mg/kg body weight), which reduced the number of macrophages in the peripheral nerves by 70\%. The treated mice showed attenuated demyelination, less muscle denervation and preserved muscle strength. This indicates that macrophage-driven inflammation in the peripheral nerves is partially responsible for the age-related neuropathy in mice. Based on previous observations that systemic inflammation can accelerate disease progression in mouse models of neurodegenerative diseases, it was hypothesized that systemic inflammation can exacerbate the peripheral neuropathy found in aged mice. To investigate this hypothesis, aged C57BL/6 mice were intraperitoneally injected with a single dose of lipopolysaccharide (LPS; 500 μg/kg body weight) to induce systemic inflammation by mimicking bacterial infection, mostly via activation of Toll-like receptors (TLRs). Altered endoneurial macrophage activation, highlighted by Trem2 downregulation, was found in LPS injected aged mice one month after injection. This was accompanied by a so far rarely observed form of axonal perturbation, i.e., the occurrence of "dark axons" characterized by a damaged cytoskeleton and an increased overall electron density of the axoplasm. At the same time, however, LPS injection reduced demyelination and muscle denervation in aged mice. Interestingly, TREM2 deficiency in aged mice led to similar changes to LPS injection. This suggests that LPS injection likely mitigates aging-related demyelination and muscle denervation via Trem2 downregulation. Taken together, this study reveals the role of macrophage-driven inflammation as a pathogenic mediator in age-related peripheral neuropathy, and that targeting macrophages might be an option to mitigate peripheral neuropathies in aging individuals. Furthermore, this study shows that systemic inflammation may be an ambivalent modifier of age-related nerve damage, leading to a distinct type of axonal perturbation, but in addition to functionally counteracting, dampened demyelination and muscle denervation. Translationally, it is plausible to assume that tipping the balance of macrophage polarization to one direction or the other may determine the functional outcome in the aging peripheral nervous system of the elderly.},
  subject      = {Maus},
  language  = {en}
}
@phdthesis{Yin2023,
  author    = {Yin, Jing},
  title     = {Progressive alterations of pro- and antidegeneration markers in the nigrostriatal tract of the AAV1/2-A53T-α synuclein rat model of Parkinson's disease},
  doi       = {10.25972/OPUS-26064},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-260645},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Neurodegeneration plays an essential role in Parkinson's disease (PD). Several crucial neuronal pro-and antidegeneration markers were described to be altered in disease models accompanied by neurodegeneration. In the AAV1/2-A53T-aSyn PD rat model progressive time-dependent motor impairment and neurodegeneration in the nigrostriatal tract starting from 2 weeks after PD model induction could be found. Downregulation of Nrf2 in SN and nigrostriatal axon localization, a trend of Tau downregulation in SN and upregulation in axon localization in the AAV1/2-A53T-aSyn PD rat model were observed, indicating potential therapeutic value of these two molecular targets in PD. No alterations of SARM1 and NMNAT2 could be detected, indicating little relevance of these two molecules with our AAV1/2-A53T-aSyn rat model.},
  language  = {en}
}
@phdthesis{Grohmann2023,
  author    = {Grohmann, Christoph},
  title     = {Kognitive Leistungsf{\"a}higkeit und Lebensqualit{\"a}t bei minimaler hepatischer Enzephalopathie - eine Pilotstudie zum Patient Reported Outcome in der Verlaufsdiagnostik},
  doi       = {10.25972/OPUS-30537},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-305375},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Die WHO definiert Gesundheit als v{\"o}lliges k{\"o}rperliches, geistiges und soziales Wohlbefinden. W{\"a}hrend diese ganzheitliche Betrachtungsweise seit Menschengedenken nahezu weltweit das Gesundheitswesen pr{\"a}gt, hat die Medizin in Europa mit der naturwissenschaftlichen Erkenntnisrevolution einen Sonderweg eingeschlagen. Hier wird der kranke Organismus in erster Linie als defekter Apparat gesehen, der mit ausgekl{\"u}gelter Technik zu reparieren ist. Aber auch pr{\"a}ziseste Qualit{\"a}tsarbeit st{\"o}ßt dabei oft an Leistungsgrenzen, weil sie als seelenlos erlebt wird. Daher sehen heute viele Fachgebiete die Notwendigkeit, ihre Behandlungskonzepte zu beseelen und ihre Behandlungserfolge auch anhand der subjektiv von Patienten empfundenen Lebensqualit{\"a}t zu beurteilen. F{\"u}r die Ermittlung dieses PRO kommen etablierte psychometrische Testverfahren in Frage, die sich auch f{\"u}r routinem{\"a}ßige Verlaufskontrollen eignen. In der vorliegenden Arbeit wurde am Beispiel der mHE gepr{\"u}ft, welchen Nutzen eine PRO-Bestimmung bei der Verlaufskontrolle haben kann. Dazu wurde eine prospektive Studie mit anf{\"a}nglich 75 Patienten durchgef{\"u}hrt. Alle hatten eine mHE und waren entweder alkoholbedingt oder aus anderen Gr{\"u}nden schwer leberkrank. An vier Terminen im Abstand von sechs Monaten wurden die kognitive Leistungsf{\"a}higkeit und der emotionale Status {\"u}berpr{\"u}ft. Die Patienten zeigten anf{\"a}nglich kognitive Einschr{\"a}nkungen, die sich im Verlauf der individuell abgestimmten Behandlung deutlich verbesserten oder ganz verschwanden. Die globale Testung mit dem MoCA ergab eine hochsignifikante Normalisierung im ersten Behandlungsjahr. Die MoCA-Werte am Studienanfang und -ende waren von der Erkrankungsursache unabh{\"a}ngig. Dieser Befund differenzierte sich in den Spezialtests TMT, PHES und NHPT. Hier zeigten die alkoholbedingt Erkrankten durchweg schlechtere Leistungen als die nicht-alkoholbedingt Erkrankten, erholten sich aber in der Regel auch deutlicher. Die seelische Gestimmtheit gem{\"a}ß BDI-II und die mit dem SF-36 MCS ermittelte psychosoziale Befindlichkeit waren in beiden Patientengruppen von Anfang an vergleichsweise g{\"u}nstig. Dabei hatten die alkoholbedingt Erkrankten die besseren Werte, speziell der BDI-II zeigte bei ihnen nach einem halben Jahr eine zus{\"a}tzliche und bleibende Stimmungsaufhellung an. Der SF-36 PCS zum K{\"o}rpererleben zeigte hingegen, dass sich die alkoholbedingt Erkrankten zu Studienbeginn in einer deutlich schlechteren Verfassung befanden. Diese verbesserte sich aber kontinuierlich, sodass nach 1,5 Jahren kein Unterschied mehr zu den nicht-alkoholbedingt Erkrankten bestand. Aus diesen Befunden und dem reichhaltigen Erfahrungsgut zur Alkoholkrankheit wird geschlossen, dass der Genesungsprozess bei alkoholbedingtem Leberversagen viel komplexer ist als bei nicht-alkoholbedingtem Leberversagen. Er k{\"o}nnte wesentlich mehr Zeit erfordern und wird offensichtlich anders erlebt. Dieser Patientengruppe k{\"o}nnten besondere physio- und gespr{\"a}chstherapeutische Angebote eine große Hilfe sein. Die Arbeit zeigt, dass es m{\"o}glich ist, mit wenig Aufwand komplement{\"a}r zu den klinischen Verlaufsbefunden einen informativen PRO-Bericht zu erhalten. Er hilft Angeh{\"o}rigen und medizinischem Personal, die pers{\"o}nlichen N{\"o}te und Hoffnungen der Patienten besser zu verstehen und gegebenenfalls einen Korrekturbedarf im Umgang zu erkennen. Hinzu kam im vorliegenden Fall die Erkenntnis, dass die alkoholbedingt Erkrankten in ihrem Kranksein anders betroffen waren. Die Gr{\"u}nde daf{\"u}r sind im Nachhinein plausibel, der Sachverhalt als solcher w{\"a}re aber ohne diese Spezialuntersuchung wohl nicht erkannt worden. Das Beispiel der PRO-Ermittlung bei der mHE macht den praktischen Wert einer Ber{\"u}cksichtigung des gesamtheitlichen Gesundheitskonzepts der WHO auch in der technikzentrierten „westlichen Medizin" deutlich.},
  subject      = {Encephalopathia hepatica},
  language  = {de}
}
@phdthesis{Zeumer2023,
  author    = {Zeumer, Karolina},
  title     = {Die Rolle dendritischer Zellen beim isch{\"a}mischen Schlaganfall},
  doi       = {10.25972/OPUS-30258},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-302580},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Ziel dieser Studie war es, zu untersuchen, ob dendritische Zellen eine Rolle beim isch{\"a}mischen Schlaganfall spielen. Zur Beantwortung dieser Fragestellung wurde ein Mausmodell gew{\"a}hlt, in dem es nach Administration von Diphterietoxin zur selektiven Depletion CD11c positiver Zellen kommt (C.FVB-Tg(Itgax-DTR/EGFP)57Lan/J). Hierbei wird der Diphterietoxinrezeptor unter dem CD11c Promotor (ITGAX) exprimiert. Aufgrund der Wiederherstellung dendritischer Zellen nach ca. 24 Stunden waren wiederholte Applikationen von Diphterietoxin notwendig. Die Zusammensetzung anderer Immunzellen wurde dabei im Wesentlichen nicht ge{\"a}ndert. F{\"u}r eine Schlaganfallinduktion wurde eine tMCAO (transient middle cerebral artery occlusion) durchgef{\"u}hrt. Hierbei wird durch Okklusion der A. cerebri media mittels Verschlussfilament f{\"u}r 30 oder 60 Minuten ein Schlaganfall im Mediastromgebiet induziert. Es wurden unterschiedliche Verschlusszeiten, Zeitpunkte und Depletionsraten untersucht. In keinem der Versuchsans{\"a}tze kam es zu einer signifikanten Ver{\"a}nderung des Schlaganfallvolumens nach Depletion CD11c positiver Zellen. Mittels quantitativer real-time PCR wurde die Expression unterschiedlicher Zytokine nach tMCAO und CD11c-Depletion untersucht. An Tag 1 nach Schlaganfallinduktion und hoher Depletionsrate ergab sich eine Verminderung der Expression von IL-1β und IL-6, w{\"a}hrend an Tag 3 und niedriger Depletionsrate die Expression dieser Zytokine nach CD11c-Depletion zunahm. Grund hierf{\"u}r k{\"o}nnte die Expression dieser Zytokine durch andere Zellen des Immunsystems, wie etwa neutrophile Granulozyten oder Mikroglia/Makrophagen sein, die m{\"o}glicherweise einer regulatorischen Funktion durch die Interaktion von Dendritischen Zellen und regulatorischen T-Zellen unterliegen. Weitere experimentelle Ans{\"a}tze sind notwendig, um diese Fragestellung beantworten zu k{\"o}nnen. TGF-β zeigte durchgehend in allen Versuchsanordnungen eine verminderte Expression nach der Depletion dendritischer Zellen. Es ist naheliegend, dass dieses neuroprotektiv-regulatorische Zytokin direkt einer Produktion durch dendritische Zellen oder von nachfolgend aktivierten T-Zellen unterliegt. In immunhistochemischen Studien konnte des Weiteren keine {\"A}nderung des Immigrationsverhaltens von CD11b+ Zellen ins Gehirn gesehen werden. Diese Studie unterliegt jedoch einigen Limitationen. So stellte sich im Laufe der Experimente heraus, dass die wiederholte Applikation von Diphterietoxin zu einer erh{\"o}hten Mortalit{\"a}t der Versuchstiere f{\"u}hrte. Nach Fertigstellung der Experimente erschien hierzu eine Publikation, welche die wiederholte Administration von DTX und die Entwicklung einer Myokarditis im gew{\"a}hlten Mausmodell in Zusammenhang brachte.},
  subject      = {Schlaganfall},
  language  = {de}
}
@phdthesis{Ostertag2023,
  author    = {Ostertag, Viktoria Charlotte Caroline},
  title     = {Pr{\"a}ventive und therapeutische Behandlung mit einem CSF-1-Rezeptorinhibitor bei verschiedenen Charcot-Marie-Tooth Mausmodellen},
  doi       = {10.25972/OPUS-30852},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-308528},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {Die Charcot-Marie-Tooth-Neuropathie umfasst eine heterogene Gruppe von erblichen unter anderem demyelinisierenden Erkrankungen des peripheren Nervensystems. Trotz ihrer hohen Pr{\"a}valenz von 1:2.500 gibt es bis dato keine kausalen Therapiem{\"o}glichkeiten. Durch den progressiven Krankheitsverlauf wird die Lebensqualit{\"a}t der Patienten stetig gemindert; der fortschreitende Verlust der Muskelkraft und St{\"o}rungen des Gangbildes sind besonders belastend. Urs{\"a}chlich f{\"u}r die CMT1-Neuropathie sind unter anderem Mutationen in Genen, die f{\"u}r Molek{\"u}le des Myelins von Schwannzellen codieren. Diese Mutationen f{\"u}hren zu einer verminderten Stabilit{\"a}t und Funktion des Myelins und so letzten Endes zu einer Demyelinisierung und axonalen Sch{\"a}digung der peripheren Nerven. Weitere Studien in CMT1-Mausmodellen zeigten jedoch, dass nicht nur die verringerte Myelinstabilit{\"a}t sondern auch eine durch das Immunsystem vermittelte geringgradige Entz{\"u}ndungsreaktion f{\"u}r die Symptome urs{\"a}chlich sein k{\"o}nnte. Hier spielen vor allem Makrophagen eine zentrale Rolle. Das Zytokin CSF-1 aktiviert die Makrophagen und verursacht so eine Demyelinisierung der peripheren Nerven. In P0het und Cx32def Mausmodellen konnte nachgewiesen werden, dass eine medikament{\"o}se Inhibition des CSF-1-Rezeptors an Makrophagen zu einem verbesserten Nervph{\"a}notypen und einer deutlichen Abmilderung des Krankheitsbildes f{\"u}hrte. In dieser Arbeit wurden in P0het und Cx32def Mausmodellen weiterf{\"u}hrende Behandlungsstudien mit einem CSF-1-RI durchgef{\"u}hrt, die untersuchen, zu welchem Zeitpunkt innerhalb des Krankheitsverlaufs (therapeutisch oder pr{\"a}ventiv) eine erfolgreiche Therapie noch m{\"o}glich ist und ob bei einem fr{\"u}heren Beginn eine noch bessere Wirkung erzielt werden kann. Abh{\"a}ngig von den verschiedenen Start- und Endpunkten waren unterschiedliche Ergebnisse zu beobachten: Hinsichtlich der klinischen Parameter wie der Greifkraft und der Anzahl an abnormal innervierten Synapsen zeigten die Tiere im pr{\"a}ventiven Behandlungszweig in beiden Mausmodellen das beste Ergebnis im Vergleich zu den Kontrolltieren. Diese substantielle Verbesserung ließ sich unabh{\"a}ngig von einem Makrophagen-Reflux sogar noch 6 Monate nach Behandlungsabbruch nachweisen. Bez{\"u}glich der endoneuralen Makrophagendepletion war sowohl in den P0het als auch den Cx32def Tieren im pr{\"a}ventiven sowie im therapeutischen Behandlungszweig eine signifikante Verbesserung zu beobachten. Diese Ergebnisse heben ein weiteres Mal die Bedeutung der Makrophagen als Teil einer Entz{\"u}ndungsreaktion in der Pathogenese der CMT1-Neuropathie hervor. Des Weiteren konnte die These gefestigt werden, dass eine Inhibition des CSF-1-Rezeptors zu verbesserten histopathologischen sowie funktionellen Parametern f{\"u}hrt. Um ein gutes Ansprechen auf die Therapie zu erzielen, m{\"u}ssen ein m{\"o}glichst fr{\"u}her Therapiebeginn sowie eine nachhaltige Behandlungsdauer gew{\"a}hrleistet sein.},
  subject      = {Charcot-Marie-Syndrom},
  language  = {de}
}
@article{KressEgenolfSommeretal.2023,
  author    = {Kreß, Luisa and Egenolf, Nadine and Sommer, Claudia and {\"U}{\c{c}}eyler, Nurcan},
  title     = {Cytokine expression profiles in white blood cells of patients with small fiber neuropathy},
  series = {BMC Neuroscience},
  volume    = {24},
  journal   = {BMC Neuroscience},
  number    = {1},
  doi       = {10.1186/s12868-022-00770-4},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-300619},
  year      = {2023},
  abstract  = {Background The role of cytokines in the pathophysiology, diagnosis, and prognosis of small fiber neuropathy (SFN) is incompletely understood. We studied expression profiles of selected pro- and anti-inflammatory cytokines in RNA from white blood cells (WBC) of patients with a medical history and a clinical phenotype suggestive for SFN and compared data with healthy controls. Methods We prospectively recruited 52 patients and 21 age- and sex-matched healthy controls. Study participants were characterized in detail and underwent complete neurological examination. Venous blood was drawn for routine and extended laboratory tests, and for WBC isolation. Systemic RNA expression profiles of the pro-inflammatory cytokines interleukin (IL)-1ß, IL-2, IL-8, tumor necrosis factor-alpha (TNF) and the anti-inflammatory cytokines IL-4, IL-10, transforming growth factor beta-1 (TGF) were analyzed. Protein levels of IL-2, IL-8, and TNF were measured in serum of patients and controls. Receiver operating characteristic (ROC)-curve analysis was used to determine the accuracy of IL-2, IL-8, and TNF in differentiating patients and controls. To compare the potential discriminatory efficacy of single versus combined cytokines, equality of different AUCs was tested. Results WBC gene expression of IL-2, IL-8, and TNF was higher in patients compared to healthy controls (IL-2: p = 0.02; IL-8: p = 0.009; TNF: p = 0.03) and discriminated between the groups (area under the curve (AUC) ≥ 0.68 for each cytokine) with highest diagnostic accuracy reached by combining the three cytokines (AUC = 0.81, sensitivity = 70\%, specificity = 86\%). Subgroup analysis revealed the following differences: IL-8 and TNF gene expression levels were higher in female patients compared to female controls (IL-8: p = 0.01; TNF: p = 0.03). The combination of TNF with IL-2 and TNF with IL-2 and IL-8 discriminated best between the study groups. IL-2 was higher expressed in patients with moderate pain compared to those with severe pain (p = 0.02). Patients with acral pain showed higher IL-10 gene expression compared to patients with generalized pain (p = 0.004). We further found a negative correlation between the relative gene expression of IL-2 and current pain intensity (p = 0.02). Serum protein levels of IL-2, IL-8, and TNF did not differ between patients and controls. Conclusions We identified higher systemic gene expression of IL-2, IL-8, and TNF in SFN patients than in controls, which may be of potential relevance for diagnostics and patient stratification.},
  language  = {en}
}
@phdthesis{Wagenhaeuser2023,
  author    = {Wagenh{\"a}user, Laura Maria},
  title     = {Die Auswirkungen der X-Inaktivierung auf den klinischen Ph{\"a}notyp bei Patientinnen mit Morbus Fabry},
  doi       = {10.25972/OPUS-31153},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-311530},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {M. Fabry ist eine X-chromosomal vererbte Stoffwechselerkrankung. Die Mutation im α-Galactosidase A Gen f{\"u}hrt zur reduzierten Aktivit{\"a}t des Enzyms und zur Akkumulation der Stoffwechselprodukte im gesamten K{\"o}rper. Von der daraus resultierenden Multiorganerkrankung sind sowohl M{\"a}nner, als auch Frauen betroffen. Als Grund hierf{\"u}r steht eine verschobene X-Inaktivierung zur Diskussion. In der vorliegenden Arbeit wurden 104 Frauen rekrutiert und die X-Inaktivierungsmuster in Mundschleimhautepithel, Blut und Hautfibroblasten untersucht. Es wurden umfangreiche klinische und laborchemische Untersuchungen durchgef{\"u}hrt, sodass von jeder Patientin ein klinischer Ph{\"a}notyp vorlag, der mit Hilfe eines numerischen Scores klassifiziert wurde. Es zeigte sich, dass Blut ein leicht zu asservierendes Biomaterial mit einer hohen Pr{\"a}valenz an verschobenen X-Inaktivierungsmustern darstellt. Eine signifikante Korrelation mit dem klinischen Ph{\"a}notyp konnte in keinem der drei untersuchten Gewebe nachgewiesen werden.},
  subject      = {Fabry-Krankheit},
  language  = {de}
}
@phdthesis{Aster2023,
  author    = {Aster, Hans-Christoph},
  title     = {Characterization of subgroups in fibromyalgia syndrome},
  doi       = {10.25972/OPUS-31304},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-313049},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {The present cumulative dissertation summarizes three clinical studies, which examine subgroups of patients within the fibromyalgia syndrome (FMS). FMS entails chronic pain and associated symptoms, and its pathophysiology is incompletely understood (1). Previous studies show that there is a subgroup of patients with FMS with objective histological pathology of the small nerve fibers of the peripheral nervous system (PNS). Another subgroup of FMS patients does not show any signs of pathological changes of the small nerve fibers. The aim of this dissertation was to compare FMS patients with healthy controls, and these two FMS subgroups for differences in the central nervous system (CNS) in order to explore possible interactions between PNS and the CNS. Regarding the CNS, differences of FMS patients with healthy controls have already been found in studies with small sample sizes, but no subgroups have yet been identified. Another aim of this thesis was to test whether the subgroups show a different response to different classes of pain medication. The methods used in this thesis are structural and functional magnetic resonance imaging (MRI), magnetic resonance diffusion imaging and magnetic resonance spectroscopy. For the evaluation of clinical symptoms, we used standardized questionnaires. The subgroups with and without pathologies of the PNS were determined by skin biopsies of the right thigh and lower leg based on the intraepidermal nerve fiber density (IENFD) of the small nerve fibers. 1) In the first MRI study, 43 female patients with the diagnosis of FMS and 40 healthy control subjects, matched in age and body mass index, were examined with different MRI sequences. Cortical thickness was investigated by structural T1 imaging, white matter integrity by diffusion tensor imaging and functional connectivity within neuronal networks by functional resting state MRI. Compared to the controls, FMS patients had a lower cortical volume in bilateral frontotemporoparietal regions and the left insula, but a higher cortical volume in the left pericalcarine cortex. Compared to the subgroup without PNS pathology, the subgroup with PNS pathology had lower cortical volume in both pericalcarine cortices. Diffusion tensor imaging revealed an increased fractional anisotropy (FA) of FMS patients in corticospinal pathways such as the corona radiata, but also in regions of the limbic systems such as the fornix and cingulum. Subgroup comparison again revealed lower mean FA values of the posterior thalamic radiation and the posterior limb of the left internal capsule in the subgroup with PNS pathology. In the functional connectivity analysis FMS patients, compared to controls, showed a hypoconnectivity between the right median frontal gyrus and the posterior cerebellum and the right crus cerebellum, respectively. In the subgroup comparisons, the subgroup with PNS pathology showed a hyperconnectivity between both inferior frontal gyri, the right posterior parietal cortex and the right angular gyrus. In summary, these results show that differences in brain morphology and functional connectivity exist between FMS patients with and without PNS pathology. These differences were not associated with symptom duration or severity and, in some cases, have not yet been described in the context of FMS. The differences in brain morphology and connectivity between subgroups could also lead to a differential response to treatment with centrally acting drugs. Further imaging studies with FMS patients should take into account this heterogeneity of FMS patient cohorts. 2) Following the results from the first MRI study, drug therapies of FMS patients and their treatment response were compared between PNS subgroups. As there is no licensed drug for FMS in Europe, the German S3 guideline recommends amitriptyline, duloxetine and pregabalin for temporary use. In order to examine the current drug use in FMS patients in Germany on a cross-sectional basis, 156 patients with FMS were systematically interviewed. The drugs most frequently used to treat pain in FMS were non-steroidal anti-inflammatory drugs (NSAIDs) (28.9\%), metamizole (15.4\%) and amitriptyline (8.8\%). Pain relief assessed by patients on a numerical rating scale from 0-10 averaged 2.2 points for NSAIDs, 2.0 for metamizole and 1.5 for amitriptyline. Drugs that were discontinued for lack of efficacy and not for side effects were acetaminophen (100\%), flupirtine (91.7\%), selective serotonin reuptake inhibitors (81.8\%), NSAIDs (83.7\%) and weak opioids (74.1\%). Patients were divided into subgroups with and without PNS pathology as determined by skin biopsies. We found no differences in drug use and effect between the subgroups. Taken together, these results show that many FMS patients take medication that is not in accordance with the guidelines. The reduction of symptoms was best achieved with metamizole and NSAIDs. Further longitudinal studies on medication in FMS are necessary to obtain clearer treatment recommendations. 3) Derived from previous pharmacological and imaging studies (with smaller case numbers), there is a hypothesis in the FMS literature that hyperreactivity of the insular cortex may have an impact on FMS. The hyperreactivity seems to be due to an increased concentration of the excitatory neurotransmitter glutamate in the insular cortex of FMS patients. The hypothesis is supported by magnetic resonance spectroscopy studies with small number of cases, as well as results from pharmacological studies with glutamate-inhibiting medication. Studies from animal models have also shown that an artificially induced increase in glutamate in the insular cortex can lead to reduced skin innervation. Therefore, the aim of this study was to compare glutamate and GABA concentrations in the insular cortex of FMS patients with those of healthy controls using magnetic resonance imaging. There was no significant difference of both neurotransmitters between the groups. In addition, there was no correlation between the neurotransmitter concentrations and the severity of clinical symptoms. There were also no differences in neurotransmitter concentrations between the subgroups with and without PNS pathology. In conclusion, our study could not show any evidence of a correlation of glutamate and GABA concentrations with the symptoms of FMS or the pathogenesis of subgroups with PNS pathologies.},
  subject      = {Fibromyalgie},
  language  = {en}
}
@phdthesis{Behnke2023,
  author    = {Behnke, Jennifer Kim},
  title     = {Charakterisierung der Krankheitsprogression im genetischen hm\(^2\)α-SYN-39 Mausmodell des Morbus Parkinson},
  doi       = {10.25972/OPUS-30204},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-302040},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2023},
  abstract  = {In dieser Arbeit wurde die Krankheitsprogression im Parkinson-Mausmodell hm2α-SYN-39 mit zunehmendem Alter charakterisiert. Die M{\"a}use wurden in 4 Altersgruppen (2-3, 7-8, 11-12, 16-17 Monate) mit motorischen Verhaltenstests auf einen Parkinson-Ph{\"a}notyp untersucht. Zudem erfolgten Untersuchungen des dopaminergen Systems zur Detektion von neurochemischen Ver{\"a}nderungen und einer Neurodegeneration im nigrostriatalen Trakt. Weiterhin wurden neuroinflammatorische Prozesse des adaptiven und angeborenen IS in der SN und im Striatum mittels immunhistochemischer F{\"a}rbungen beurteilt. Ein Parkinson-Ph{\"a}notyp in diesem Mausmodell zeigte sich nur leicht ausgepr{\"a}gt, sodass der Rotarod- und Zylinder-Test lediglich den Hinweis auf eine nicht-signifikante Einschr{\"a}nkung der Motorik erbrachte. Dennoch ergab die stereologische Quantifizierung TH- und Nissl-positiver Zellen in der SNpc der hm2α-SYN-39 M{\"a}use eine altersabh{\"a}ngige, signifikant-progrediente Reduktion der dopaminergen Neurone mit zunehmendem Alter. Eine signifikant niedrigere TH-positive Zellzahl dieser tg M{\"a}use zeigte sich ab einem Alter von 16-17 Monaten verglichen zu gleichaltrigen wt Tieren. Dagegen war die Neurodegeneration im Striatum etwas weniger ausgepr{\"a}gt. Die tg M{\"a}use pr{\"a}sentierten im Alter von 16-17 Monaten eine nicht-signifikante Erniedrigung der dopaminergen Terminalen verglichen zu gleichaltrigen wt Tieren. Ein DA-Mangel im Striatum der tg M{\"a}use konnte mittels HPLC best{\"a}tigt werden. Bis zum Alter von 16-17 Monaten wurde eine signifikante Reduktion der DA-Level von 23,2 \% verglichen zu gleichaltrigen wt M{\"a}usen gezeigt. Außerdem erniedrigt waren die striatalen Level von NA und 5-HAT bei tg M{\"a}usen, passend zu den bisherigen Ergebnissen bei Parkinson-Patienten. Immunhistochemische Untersuchungen einer Neuroinflammation im nigrostriatalen Trakt ergaben eine tendenziell erh{\"o}hte Infiltration von CD4- und CD8-positiven T-Zellen bei hm2α-SYN-39 M{\"a}usen mit zunehmendem Alter, wobei die Infiltration CD8-positiver Zellen ausgepr{\"a}gter war als bei CD4-positiven Zellen. Eine noch deutlichere neuroinflammatorische Reaktion zeigte das angeborene IS. Hierbei ergab die immunhistologische Quantifizierung CD11b-positiver mikroglialer Zellen einen hochsignifikanten Anstieg im nigrostriatalen Trakt bei hm2α-SYN-39 M{\"a}usen schon im jungen Alter. Zusammenfassend pr{\"a}sentierte dieses Parkinson-Mausmodell eine langsam-progrediente Parkinson-Pathologie mit begleitender Neuroinflammation im nigrostriatalen Trakt w{\"a}hrend des Alterns, wobei die Immunantwort der mikroglialen Zellen zu einem fr{\"u}heren Zeitpunkt einsetzte als die T-Zellinfiltration und Neurodegeneration. Dieses Mausmodell bietet zahlreiche M{\"o}glichkeiten zur zuk{\"u}nftigen Erforschung der Pathophysiologie beim MP. Generell weist diese Arbeit auf eine bedeutende Rolle neuroinflammatorischer Prozesse in der Krankheitsprogression der Parkinsonerkrankung hin und soll dazu ermutigen Neuroinflammation durchaus intensiver in tg Tiermodellen zu untersuchen.},
  subject      = {Parkinson-Krankheit},
  language  = {de}
}